Melior Discovery Signs Development Deal With Johnson & Johnson
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J is third big pharma firm to sign on to use Melior’s in vivo theraTrace therapeutic indications screening platform.
You may also be interested in...
Melior Will Screen AstraZeneca Compounds For Therapeutic Activity
Meanwhile, the discovery firm plans to spin off a diabetes drug company with its own lead compound MLR-1023.
Melior Will Screen AstraZeneca Compounds For Therapeutic Activity
Meanwhile, the discovery firm plans to spin off a diabetes drug company with its own lead compound MLR-1023.
Melior, Pfizer Trade Diabetes License Option For Data
Data from Pfizer on “recycled” gastric-ulcer drug will help move it into humans, Melior CEO tells “The Pink Sheet” DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: